Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $2.4 million.

  • Enanta Pharmaceuticals' Interest & Investment Income fell 1346.91% to $2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.1 million, marking a year-over-year decrease of 3169.32%. This contributed to the annual value of $9.4 million for FY2025, which is 3607.31% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Interest & Investment Income stood at $2.4 million for Q4 2025, which was down 1346.91% from $2.1 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Interest & Investment Income's 5-year high stood at $4.7 million during Q3 2023, with a 5-year trough of $255000.0 in Q1 2022.
  • For the 5-year period, Enanta Pharmaceuticals' Interest & Investment Income averaged around $2.3 million, with its median value being $2.3 million (2025).
  • In the last 5 years, Enanta Pharmaceuticals' Interest & Investment Income surged by 88371.5% in 2023 and then plummeted by 3982.67% in 2025.
  • Enanta Pharmaceuticals' Interest & Investment Income (Quarter) stood at $258000.0 in 2021, then soared by 284.88% to $993000.0 in 2022, then soared by 332.83% to $4.3 million in 2023, then tumbled by 34.88% to $2.8 million in 2024, then decreased by 13.47% to $2.4 million in 2025.
  • Its Interest & Investment Income was $2.4 million in Q4 2025, compared to $2.1 million in Q3 2025 and $2.3 million in Q2 2025.